Literature DB >> 28625610

Current progress in antivascular tumor therapy.

Yi-Ju Ho1, Tzu-Chia Wang1, Ching-Hsiang Fan1, Chih-Kuang Yeh2.   

Abstract

The tumor vasculature transports oxygen, nutrients and drugs for crucial roles in tumor therapy. Antivascular therapy directly targets existing tumor vessels to reduce blood perfusion and then inhibit tumor growth. Vascular disrupting agents and ultrasound-stimulated microbubble destruction use chemical toxicity and physical effect, respectively, to damage vascular endothelial cells for antivascular therapy. Moreover, antivascular therapy can break vessel wall barriers and change the tumor microenvironment to compensate for the limitations of conventional chemotherapy or radiotherapy. This review presents current progress and an overview of antivascular therapy, which can inform the development and application in cancer research.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28625610     DOI: 10.1016/j.drudis.2017.06.001

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  5 in total

Review 1.  Ultrasonic technologies in imaging and drug delivery.

Authors:  Yi-Ju Ho; Chih-Chung Huang; Ching-Hsiang Fan; Hao-Li Liu; Chih-Kuang Yeh
Journal:  Cell Mol Life Sci       Date:  2021-07-23       Impact factor: 9.261

Review 2.  Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers.

Authors:  Khalid El Bairi; Mariam Amrani; Said Afqir
Journal:  Cancer Med       Date:  2018-05-06       Impact factor: 4.452

3.  Microbubble-enhanced ultrasound for the antivascular treatment and monitoring of hepatocellular carcinoma.

Authors:  Julia C D'Souza; Laith R Sultan; Stephen J Hunt; Terence P Gade; Mrigendra B Karmacharya; Susan M Schultz; Angela K Brice; Andrew K W Wood; Chandra M Sehgal
Journal:  Nanotheranostics       Date:  2019-10-01

4.  Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.

Authors:  Bonan Zhao; Zhipeng Dong; Weixing Liu; Fangning Lou; Qiyan Wang; Hao Hong; Yue Wang
Journal:  J Nanobiotechnology       Date:  2021-05-01       Impact factor: 9.429

5.  Occurrence of hyperprogressive disease following administration of immune checkpoint inhibitors in lung squamous cell carcinoma: A case report.

Authors:  Shixia Dong; Kunjing Liu; Ruijuan Liu; Jing Zhuang
Journal:  Exp Ther Med       Date:  2022-08-08       Impact factor: 2.751

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.